Syncom Formulations India Ltd-$
Syncom Formulations India Ltd-$ (SYNCOMF) last reported results for the quarter ended Jun 2026, with sales of ₹126 crore and net profit of ₹25 crore. The stock last traded at ₹23.4, a market capitalisation of ₹2,201 crore, on a P/E of 25.7. Over the past 52 weeks the stock has ranged between ₹10.2 and ₹27.5. Figures are as of 6 Oct 2026 and are not real time.
Syncom Formulations India Ltd-$ share price and key metrics
- Current price
- ₹23.4
- Market cap
- ₹2,201 cr
- Stock P/E
- 25.7
- Book value
- ₹4.41
- ROE
- 17.6%
- ROCE
- 24.7%
- Dividend yield
- 0.43%
- 52w high / low
- 27.5/10.2
Metrics as of 6 Oct 2026. Not real time.
Track Syncom Formulations India Ltd-$
Cruxal reads every Syncom Formulations India Ltd-$ filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Syncom Formulations India Ltd-$ growth and returns
- 10 Years
- 10%
- 5 Years
- %
- 3 Years
- 30%
- TTM
- 0%
- 10 Years
- 20%
- 5 Years
- %
- 3 Years
- 50%
- TTM
- 49%
- 10 Years
- 25%
- 5 Years
- 20%
- 3 Years
- 35%
- 1 Year
- 41%
- 10 Years
- %
- 5 Years
- 13%
- 3 Years
- 15%
- Last Year
- 18%
Syncom Formulations India Ltd-$ quarterly results
In the quarter ended Jun 2026, sales were ₹126 cr, up 7.7% from ₹117 cr a year earlier. Net profit was ₹25 cr, up 56.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 102 | 128 | 149 | 117 | 122 | 115 | 135 | 126 |
| Expenses | 90 | 113 | 131 | 101 | 103 | 94 | 113 | 99 |
| Operating profit | 12 | 15 | 18 | 16 | 18 | 21 | 22 | 26 |
| OPM % | 12% | 12% | 12% | 14% | 15% | 18% | 16% | 21% |
| Other income | 4 | 4 | 7 | 6 | 5 | 6 | 15 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 15 | 17 | 23 | 20 | 22 | 25 | 34 | 32 |
| Tax % | 25% | 25% | 24% | 22% | 25% | 25% | 25% | 23% |
| Net profit | 11 | 13 | 18 | 16 | 17 | 19 | 25 | 25 |
| EPS (₹) | 0.12 | 0.14 | 0.19 | 0.17 | 0.18 | 0.20 | 0.27 | 0.26 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Syncom Formulations India Ltd-$ annual results
| ₹ crore | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 115 | 151 | 173 | 184 | 185 | 216 | 222 | 262 | 463 | 488 | 498 |
| Operating profit | 11 | 16 | 18 | 17 | 17 | 20 | 20 | 30 | 54 | 77 | 88 |
| OPM % | 9% | 11% | 11% | 9% | 9% | 9% | 9% | 11% | 12% | 16% | 18% |
| Net profit | 6 | 9 | 10 | 10 | 11 | 20 | 20 | 25 | 49 | 76 | 86 |
| EPS (₹) | 0.07 | 0.12 | 0.13 | 0.13 | 0.13 | 0.23 | 0.21 | 0.27 | 0.53 | 0.81 | 0.91 |
TTM is the trailing twelve months to the most recent quarter.
Syncom Formulations India Ltd-$ balance sheet
| ₹ crore | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 22 | 78 | 78 | 78 | 78 | 86 | 94 | 94 | 94 | 94 |
| Reserves | 65 | 17 | 22 | 31 | 39 | 136 | 162 | 194 | 248 | 321 |
| Borrowings | 2 | 3 | 6 | 6 | 12 | 58 | 83 | 72 | 5 | 1 |
| Other liabilities | 33 | 42 | 31 | 61 | 50 | 28 | 39 | 44 | 67 | 117 |
| Total liabilities | 123 | 140 | 138 | 175 | 180 | 308 | 378 | 405 | 413 | 534 |
| Fixed assets | 50 | 50 | 46 | 46 | 55 | 94 | 91 | 120 | 125 | 184 |
| CWIP | 0 | 0 | 0 | 5 | 0 | 6 | 26 | 0 | 0 | 0 |
| Investments | 7 | 9 | 6 | 23 | 36 | 43 | 64 | 66 | 93 | 109 |
| Other assets | 66 | 80 | 85 | 101 | 89 | 165 | 197 | 219 | 196 | 241 |
| Total assets | 123 | 140 | 138 | 175 | 180 | 308 | 378 | 405 | 413 | 534 |
As reported by the company. Total assets equal total liabilities by construction.
Syncom Formulations India Ltd-$ cash flow
| ₹ crore | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 6 | 7 | 0 | 24 | 14 | 16 | 11 | -6 | 23 | 58 |
| Cash from investing | -0 | -4 | 1 | -23 | -18 | -27 | -45 | 83 | -18 | -51 |
| Cash from financing | -6 | -1 | 1 | -2 | 5 | 8 | 35 | -15 | -68 | -3 |
| Net cash flow | -1 | 2 | 2 | -1 | 1 | -2 | 1 | 62 | -63 | 4 |
| Free cash flow | 3 | 4 | -3 | 21 | 2 | 5 | -10 | -14 | 13 | 46 |
| CFO / operating profit | 76% | 66% | 32% | 176% | 108% | 113% | 86% | 7% | 70% | 105% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Syncom Formulations India Ltd-$ operating ratios
| Per year | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 15% | 16% | 15% | 13% | — | 10% | 11% | 19% | 25% |
| Debtor days | 92 | 71 | 66 | 91 | 91 | 114 | 124 | 144 | 85 | 83 |
| Inventory days | 29 | 36 | 34 | 43 | 29 | 51 | 55 | 49 | 49 | 81 |
| Days payable | 91 | 105 | 63 | 130 | 92 | 36 | 53 | 56 | 52 | 96 |
| Cash conversion cycle | 29 | 1 | 37 | 4 | 27 | 129 | 126 | 137 | 82 | 68 |
| Working capital days | 94 | 75 | 85 | 40 | 42 | 33 | -4 | 51 | 95 | 85 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Syncom Formulations India Ltd-$ shareholding pattern
Promoters held 50.57% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.35%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% |
| FIIs | 0.10% | 0.13% | 0.11% | 0.41% | 0.10% | 0.26% | 0.21% | 0.35% |
| Public | 49.34% | 49.30% | 49.32% | 49.02% | 49.33% | 49.17% | 49.23% | 49.07% |
| No. of shareholders | 4,69,242 | 4,89,520 | 4,84,529 | 4,71,066 | 4,57,364 | 4,42,280 | 4,31,690 | 4,22,114 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Syncom Formulations India Ltd-$ corporate filings
- Certificate for Compliance of Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 30th September, 2026.Company Updatelow impact
- SYNCOM FORMULATIONS (INDIA) LIMITED declares final dividend of Rs. 0.10 per share for FY 2025-26, totaling approximately Rs. 9.4 crore Corp Actionmedium impact
Cruxal's analysis: SYNCOM FORMULATIONS (INDIA) LIMITED announced that its shareholders approved a final…
Read the full analysis - SYNCOM FORMULATIONS (INDIA) LIMITED Approves Key Director Appointments at AGM, Signaling Strategic Leadership ChangesCompany Updatemedium impact
Cruxal's analysis: SYNCOM FORMULATIONS (INDIA) LIMITED announced the appointment of Shri Rahul Vijay Bankda…
Read the full analysis - SYNCOMF declares 10% dividend for FY 2025-26; approves financial statements and key management appointmentsAGM/EGMhigh impact
Cruxal's analysis: SYNCOMF announced the approval of its FY 2025-26 financial results, with a net profit of…
Read the full analysis - SYNCOM FORMULATIONS (INDIA) LIMITED holds AGM with approval of multiple resolutions including financials, director reappointments, and dividend declarationAGM/EGMhigh impact
Cruxal's analysis: SYNCOM FORMULATIONS (INDIA) LIMITED conducted its 38th AGM on 30th September 2026 via…
Read the full analysis - Syncom Formulations (India) Limited holds 38th AGM; declares 10% dividend for FY 2025-26, with no immediate financial surprisesAGM/EGMlow impact
Cruxal's analysis: Syncom Formulations (India) Limited conducted its 38th Annual General Meeting on 30th…
Read the full analysis - Syncom Formulations Promoters Voluntarily Waive Final Dividend of 47.53 Lakh Rupees Corp Actionlow impact
Cruxal's analysis: Syncom Formulations (India) Limited has announced that its Promoters and Promoter Group…
Read the full analysis - We would like to inform you that Pursuant to the provisions of SEBI (PIT) Regulation, 2015. The window for dealing in the securities of the company shall remain closed from 1st Oct, 2026 ....Insider Trading / SASTlow impact
- Syncom Formulations India Ltd fixes September 23, 2026 as record date for dividend paymentCorp. Actionlow impact
Cruxal's analysis: Syncom Formulations India Ltd has announced Wednesday, September 23, 2026, as the record…
Read the full analysis - Syncom Formulations (India) Limited Announces 38th Annual General Meeting (AGM) and E-Voting ScheduleCompany Updatelow impact
Cruxal's analysis: Syncom Formulations (India) Limited has issued a formal notice for its 38th Annual…
Read the full analysis - Syncom Formulations India Ltd dispatches letters to shareholders for email registrationCompany Updatelow impact
Cruxal's analysis: The company has initiated a communication drive to register email addresses for…
Read the full analysis - Syncom Formulations India Ltd submits Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Syncom Formulations India Ltd has filed its Business Responsibility and Sustainability…
Read the full analysis - Syncom Formulations (India) Limited Announces 38th AGM for September 30, 2026, Including Dividend Declaration and Key Management AppointmentsCompany Updatelow impact
Cruxal's analysis: Syncom Formulations (India) Limited has scheduled its 38th Annual General Meeting for…
Read the full analysis - Syncom Formulations India Ltd to hold 38th Annual General Meeting on September 30, 2026Otherslow impact
Cruxal's analysis: Syncom Formulations India Ltd has submitted its 38th Annual Report and Notice for the…
Read the full analysis - Syncom Formulations (India) Limited Announces 38th Annual General Meeting (AGM) and Book ClosureCompany Updatelow impact
Cruxal's analysis: Syncom Formulations (India) Limited has issued a formal notice for its 38th Annual…
Read the full analysis - Syncom Formulations India Ltd submits press release under Regulation 30Company Updatelow impact
Cruxal's analysis: Syncom Formulations India Ltd has submitted a press release in compliance with Regulation…
Read the full analysis - Syncom Formulations (India) Limited Reports Unaudited Financial Results for Quarter Ended 30th June 2026Company Updatelow impact
Cruxal's analysis: Syncom Formulations (India) Limited has released its unaudited standalone and…
Read the full analysis - Syncom Formulations (India) Limited Announces Major Leadership Succession and Management RestructuringCompany Updatemedium impact
Cruxal's analysis: Syncom Formulations (India) Limited has initiated a significant leadership transition…
Read the full analysis - Syncom Formulations India Ltd schedules 38th Annual General Meeting for September 30, 2026Company Updatelow impact
Cruxal's analysis: Syncom Formulations India Ltd has issued a regulatory filing pursuant to Regulation 44 of…
Read the full analysis - Syncom Formulations (India) Limited announces appointment of Cost and Internal Auditors for FY 2026-27Company Updatelow impact
Cruxal's analysis: Syncom Formulations (India) Limited has formally appointed M/s M. Goyal & Co. as Cost…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.